Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00025532
Overview
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have gastrointestinal cancer.
Sponsor
University of California, San Francisco
Phase
Phase 1
Contacts
Margaret A. Tempero, MD (STUDY_CHAIR)
ClinicalTrials.gov
NCT00025532Help us improve your experience